T13044 |
Mevociclib
|
1816989-16-8
|
98.02%
|
|
Mevociclib (SY-1365) is a highly selective covalent inhibitor of CDK7. SY-1365 possesses therapeutic potential in both hematological and solid tumors.
|
T2653 |
SB1317
|
1204918-72-8
|
100%
|
|
SB1317 (TG02) is a potent inhibitor of cyclin dependant kinases (CDKs), Janus kinase 2 (JAK2), and Fms-like tyrosine kinase-3 (FLT3).
|
T1947 |
BS-181
|
1092443-52-1
|
|
|
BS-181 is a highly selective CDK7 inhibitor (IC50: 21 nM); >40-fold selective for CDK7 than CDK1/2/4/5/6/9.
|
TN1663 |
Ganoderic acid DM
|
173075-45-1
|
98%
|
|
Ganoderic acid DM is an antiandrogenic osteoclastogenesis inhibitor, it especially suppresses the expression of c-Fos and nuclear factor of activated T cells c1 ...
|
T17305 |
CDK8-IN-4
|
1613638-82-6
|
98%
|
|
CDK8-IN-4 is an inhibitor of CDK8 (IC50: 0.2 nM).
|
TN4394 |
Kobophenol A
|
124027-58-3
|
98%
|
|
Kobophenol A has antimicrobial, and anti-inflammatory activities, it might be a candidate for treatment of inflammatory bone diseases relevant to osteoblast cell...
|
T12617 |
(R)-CR8 trihydrochloride
|
1786438-30-9
|
98%
|
|
(R)-CR8 trihydrochloride is a potent inhibitor CDK1/2/5/7/9.
|
T5438 |
PROTAC CDK9 Degrader-1
|
2118356-96-8
|
98%
|
|
PROTAC CDK9 Degrader-1 is a selective CDK9 degrader.
|
T77923 |
BSJ-03-204 triTFA
|
|
98%
|
|
BSJ-03-204 triTFA is a potent and selective Cereblon- and CDK-targeted PROTAC (PROteolysis TArgeting Chimera) featuring Palbociclib-based ligands for the degrada...
|
T78048 |
Rel-(2S,3R)-Voruciclib hydrochloride
|
1253647-46-9
|
98%
|
|
Rel-(2S,3R)-Voruciclib hydrochloride is an enantiomer of Voruciclib hydrochloride, an orally active cyclin-dependent kinase (CDK) inhibitor.
|
T78137 |
Avotaciclib hydrochloride
|
|
98%
|
|
Avotaciclib hydrochloride, a CDK1 inhibitor, is the hydrochloride salt of Avotaciclib and exhibits potential therapeutic use in specific malignancies, including ...
|
T78813 |
CDK2/Bcl2-IN-1
|
|
98%
|
|
CDK2/Bcl2-IN-1 (compound 1) is a saponin-based inhibitor of CDK-2 (IC50=117.6 nM) that exhibits potent cytotoxic effects on cancer cells. Additionally, it inhibi...
|
T78837 |
CP-07
|
|
98%
|
|
CP-07 is a selective and effective PROTAC CDK9 degrader (DC50: 43 nM), demonstrating inhibition of 22RV1 cell proliferation (IC50: 62 nM) and colony formation by...
|
T79014 |
QR-6401
|
2845096-18-4
|
98%
|
|
QR-6401, a selective macrocyclic CDK2 inhibitor, is orally active with IC50 values of 0.37 nM for CDK2/E1, 10 nM for CDK9/T1, 22 nM for CDK1/A2, 34 nM for CDK6/D...
|
T79037 |
CDK9-IN-23
|
2761572-96-5
|
98%
|
|
CDK9-IN-23 (Example 4) is a potent inhibitor of CDK9, exhibiting an IC50 value of less than 20 nM [1].
|
T79046 |
CDK4-IN-2
|
2380320-68-1
|
98%
|
|
CDK4-IN-2 (A17) is a potent inhibitor of CDK4, exhibiting K i and IC 50 values of less than 10 nM and is utilized in cancer research [1].
|
T79112 |
CDK4/6-IN-17
|
2035069-96-4
|
98%
|
|
CDK4/6-IN-17 (compound 12) is an orally bioavailable inhibitor of CDK4/6, demonstrating potent activity with IC50 values between 10-100 nM in BE(2) cells. It has...
|
T79169 |
CDK7-IN-22
|
2173190-60-6
|
98%
|
|
CDK7-IN-22 (compound 101) is a selective CDK7 inhibitor that exhibits antitumor activity, demonstrating specificity for CDK7 [1].
|
T79354 |
CDK9-IN-24
|
|
98%
|
|
CDK9-IN-24 (compound 21a) is a potent and selective inhibitor of CDK9 that exhibits a pronounced inhibitory impact on tumor proliferation. It impedes cell growth...
|
T79367 |
CDK9-IN-27
|
|
98%
|
|
CDK9-IN-27 (Compound 6a), a CDK9 inhibitor with an IC50 of 0.424 μM, induces apoptosis and S-phase cell cycle arrest. It exhibits cytotoxicity against HepG2, HCT...
|